Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 9.01 · 8-K/A

Avantor, Inc.

AVTRNYSEEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 23, 2026, Avantor, Inc.…

Filed Aug 27, 2026Accepted Aug 27, 2026, 4:40 PM EDTCIK 1722482Accession 0001628280-26-059273
Share

Company context

Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit corporate.avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Current securities

Historical securities (2)

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 3, 2026
  2. 10-Q filingOct 28, 2026
  3. Results of Operations and Financial ConditionOct 28, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 21, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 21, 2026

Registered securities in this filing

Avantor, Inc. · 8-K/A · Filed 2026-08-27

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.01 par value

Symbol
AVTR
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000162828026059273 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 23, 2026, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) disclosing that Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, would transition to a new role supporting the Company’s segment integration activities for a period of time, after which he would depart the Company. The Original 8-K did not include Mr. Gourdier’s departure date because, at the time, his departure date had not been determined. This Form 8-K/A is being filed for the purpose of providing Mr. Gourdier’s departure date. On August 21, 2026, the Company, through its subsidiary VWR International, LLC, and Mr. Gourdier agreed to a transition arrangement (the “Transition Agreement”), pursuant to which Mr. Gourdier will continue his employment with the Company through October 14, 2026, after which his employment will end. If Mr. Gourdier remains employed and complies with the terms of the Transition Agreement until October 14, 2026, he will be entitled to receive severance benefits materially consistent with the terms of the Company’s Executive Severance and Change in Control Plan, which are described in the Company’s proxy statement filed with the Securities and Exchange Commission on March 27, 2026.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.